Lymphoma and Myeloma

MD Anderson Cancer Center is home to one of the largest multidisciplinary programs in the nation for the diagnosis and treatment of lymphoma and myeloma. With more than 35,000 patient visits annually, we offer your patients access to targeted therapies and numerous clinical trials, many only available here.

Our subspecialized physicians collaborate with and serve as a resource for referring physicians to ensure patients are matched with the best treatment options for their specific situations.

Referring Your Patient

Where you send your patient first matters.

When you refer to MD Anderson, you can have confidence that your patients will receive the highest level of subspecialized care from accurate diagnoses and correct staging of their diseases to the most advanced treatment options available.

If you suspect your patient has lymphoma or myeloma, please reach out to our Referring Provider Team right away. We’re here to help.
A Safer Environment

Patient safety is our top priority. When you refer to MD Anderson, your patients will receive the highest level of care in a safe, compassionate environment. To learn more about safety during the pandemic, visit mdanderson.org/coronavirus.

Our lymphoma and myeloma tumor board holds case conference meetings to develop comprehensive, customized treatment plans to prevent patients from receiving unnecessary treatments or procedures.

More Treatment Options for Your Patients

MD Anderson offers treatment options for your patients, including the use of less toxic doses of chemotherapy. Several new widely accepted standard therapies that limit the use of chemotherapy were developed at MD Anderson. This treatment results in higher success rates while helping maintain patients’ quality of life. Even newer versions of these approaches are available to patients interested in clinical trials. Other treatment options include:

Bone Marrow and Stem Cell Transplants
Our Stem Cell Transplantation Center is among the largest, most active programs in the nation, performing more than 800 procedures annually. This center is dedicated to monitoring and managing graft versus host disease, and we are a matched unrelated donor program, which has earned us recognition as a specialized center for stem cell transplants by the National Marrow Donor Program.

Diagnostic Testing
Our pathologists are leaders in the field and often refine a new patient’s diagnosis of lymphoma or myeloma up to 25% of the time once they arrive at MD Anderson.

Immunotherapy
We continue to evolve the use of immunotherapies, such as CAR T cell and other types of cellular therapies. These options can result in cures for patients with certain types of lymphomas and allow patients with myeloma to live full, healthy lives.

Radiation Therapy
We offer a wide array of radiation therapies, including IMRT, VMAT, proton therapy and radioimmunotherapy – a combination of radiation therapy and immunotherapy used to treat non-Hodgkin lymphoma and other cancers.
Lymphoma

Our experts have made many advances in the treatment of lymphoma. MD Anderson participates in The Lymphoma Epidemiology of Outcomes Cohort Study or LEO, the nation’s largest study following patients newly diagnosed with non-Hodgkin lymphoma with the goal of identifying clinical, epidemiologic, genetic, tumor and treatment factors to improve outcomes and quality of life for survivors. Christopher Flowers, M.D., the chair of MD Anderson’s Lymphoma and Myeloma Center, serves as a lead investigator for the LEO study.

Led by our disease expert, Michael Wang, M.D., nearly every advancement for mantle cell lymphoma over the last decade has occurred at MD Anderson.

Because there are so many varieties of lymphoma, a cure will not come from a one-treatment-fits-all approach. The MD Anderson Moon Shots Program® and Adoptive Cellular Therapy platform are research engines driving new ways to generate immune cells targeted at curing patients who relapse after standard treatments.

Myeloma

MD Anderson offers molecular testing, such as FISH, and next generation sequencing translocation. These comprehensive tests are critical to providing patients with an accurate and complete diagnosis, including correct staging of their disease.

As a leader in drug development, important discoveries in myeloma, including the development of bortezomib and lenalidomide, have been led by MD Anderson physicians. These treatments can significantly impact myeloma. New clinical trials are underway with the next generation of new drugs aiming to provide even more benefits.

We offer a wide range of clinical trials for every stage of myeloma.

Why MD Anderson

MD Anderson has one of the largest groups of physicians, researchers and clinical staff dedicated exclusively to providing care and defining new strategies to improve survival for patients with lymphoma and myeloma. As a leader in drug development, our team helped establish FDA approval of leading-edge therapies that are now considered the standard. These include CAR T cell therapy, ibrutinib, acalabrutinib, bortezomib and lenalidomide.

We also continue to advance patient care through discoveries, including management of CAR T cell toxicities, chemotherapy-free regimens, and novel tests, like cell-free DNA. With more than 100 active clinical trials, we provide innovative therapies with unique mechanisms of actions, such as bispecific antibodies, small molecules, and drug combinations. Many of these were designed by our experts.
Why MD Anderson

Consistent Communication

Our Referring Provider Team is available to help you facilitate the referral of patients and offer support in creating a login to myMDAnderson.org where you can:

- Access patient appointment schedules and medical record information
- Access transcribed patient reports and results
- Receive notifications regarding referral status and results availability
- Easily update your profile and contact information

During your patient's treatment, our team will work closely with you to help you take an active role in managing their care at MD Anderson.

Cancers We Treat

- Amyloidosis
- Follicular lymphoma
- Hodgkin lymphoma
- Mantle cell lymphoma
- Myeloma
- Non-Hodgkin lymphomas, including B-cell and T-cell lymphomas
- Waldenström's macroglobulinemia

WAYS TO REFER

THE REFERRING PROVIDER TEAM:
Phone: 877-632-6789
Fax: 713-563-2449

Monday-Friday: 8 a.m. - 11 p.m.
Saturday-Sunday: 8 a.m. - 7 p.m.

PhysicianReferrals@mdanderson.org
mdanderson.org/referral